Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834948 · ClinicalTrials.gov registry record · Phase 1
AO-176 in Multiple Solid Tumor Malignancies
A Phase 1 study of Solid Tumor, sponsored by Arch Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 10
- Study locations
NCT03834948: Completed Phase 1 study of Solid Tumor, sponsored by Arch Oncology.
NCT03834948 is a Phase 1 study of Solid Tumor that has completed, run by Arch Oncology. The registered enrollment target is 57 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (74% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03834948, a Phase 1 study of Solid Tumor, has completed, sponsored by Arch Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
Primary Outcome
Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.
Conditions Studied
Interventions
- DRUG AO-176
- DRUG AO-176 + Paclitaxel
- DRUG AO-176 + Pembrolizumab
Study Locations (10)
California
- University of Southern California - Los Angeles
- University of California San Francisco - San Francisco
Virginia
- University of Virginia - Charlottesville
- Virginia Cancer Specialists - Fairfax
Massachusetts
- Dana-Farber Cancer Institute - Boston
Oklahoma
- Oklahoma University, Stephenson Cancer Center - Oklahoma City
Oregon
- Oregon Health Science University - Portland
Pennsylvania
- Sidney Kimmel Cancer Center, Thomas Jefferson University - Philadelphia
Tennessee
- Tennessee Oncology - Nashville
Washington
- Northwest Medical Specialties - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 1 |
What the finished NCT03834948 record still lists
NCT03834948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which AO-176 is the first listed.
NCT03834948 lists 10 locations in 8 states (California, Virginia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03834948 about?
NCT03834948 is a clinical study titled "AO-176 in Multiple Solid Tumor Malignancies". This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
What is the current status of trial NCT03834948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2019-02-04. Estimated completion is 2023-02-15.
What conditions does trial NCT03834948 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT03834948?
The interventions under investigation include: AO-176 (DRUG), AO-176 + Paclitaxel (DRUG), AO-176 + Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03834948?
This trial is sponsored by Arch Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03834948 being conducted?
This trial has 10 study locations across California, Massachusetts, Oklahoma, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03834948's enrollment target sits among peer trials
57 113th of 196 higher than 84 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI